{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.23","value":"-34.71"},{"groupId":"OG001","spread":"27.07","value":"-44.13"},{"groupId":"OG002","spread":"63.71","value":"-29.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"ΔSUVpeak (Alive)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.37","value":"-42.62"},{"groupId":"OG001","spread":"34.13","value":"-34.43"},{"groupId":"OG002","spread":"22.99","value":"-46.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"47"}],"units":"Participants"}],"title":"ΔSUVpeak (Deceased)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.77","value":"-44.36"},{"groupId":"OG001","spread":"31.93","value":"-40.46"},{"groupId":"OG002","spread":"22.31","value":"-47.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"ΔSUVpeak (Alive - No progression)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.68","value":"-38.82"},{"groupId":"OG001","spread":"31.97","value":"-37.44"},{"groupId":"OG002","spread":"44.21","value":"-39.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"61"}],"units":"Participants"}],"title":"ΔSUVpeak (Progression/Deceased)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.02","value":"-39.15"},{"groupId":"OG001","spread":"25.90","value":"-42.35"},{"groupId":"OG002","spread":"57.54","value":"-37.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"title":"ΔSUVpeak (Alive - Lung Cancer progression/death)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.65","value":"-40.34"},{"groupId":"OG001","spread":"35.71","value":"-34.88"},{"groupId":"OG002","spread":"22.49","value":"-43.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"39"}],"units":"Participants"}],"title":"ΔSUVpeak (Lung Cancer progression/death)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"71"}],"units":"Participants"}],"description":"ΔSUVpeak will be measured as 100\\* (SUVpeak Mid-treatment - SUVpeak baseline)/(SUVpeak baseline) All survival measures will be measured in days from registration up to 5 years.","dispersionType":"Standard Deviation","groups":[{"description":"Patients undergo chemoradiotherapy as defined for the arm of the study to which they were randomized.\n\n18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study","id":"OG000","title":"Both Arms"},{"description":"Patients undergo standard radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FMISO-PET imaging at baseline\n\n18F-Fluoromisonidazole: Undergo FMISO PET/CT prior to therapy for patients enrolling at institutions participating in the FMISO correlative study\n\nCarboplatin: Given IV\n\nExternal Beam Radiation Therapy: Undergo radiotherapy","id":"OG001","title":"Arm I (Standard Chemoradiotherapy)"},{"description":"Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.\n\n18F-Fluoromisonidazole: Participants enrolled at institutions participating in the FMISO correlative study undergo FMISO-PET prior to treatment\n\nCarboplatin: Given IV\n\nComputed Tomography: Undergo FDG PET/CT\n\nComputed Tomography: Undergo FMISO PET/CT (Correlative studies)\n\nFludeoxyglucose F-18: Undergo FDG PET/CT\n\nImage-Guided Adaptive Radiation Therapy: Undergo individualized adaptive radiotherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nPositron Emission Tomography: Undergo FDG PET/CT\n\nPositron Emission Tomography: Undergo FMISO PET/CT (Correlative studies)","id":"OG002","title":"Arm II (Experimental Chemoradiotherapy)"}],"paramType":"MEAN","populationDescription":"As a predictive marker, relative SUVpeak is reported by survival status in each survival category. For example, Relative ΔSUVpeak is reported separately for the 38 participants who were alive at the 5 year milestone and for the 69 patients who were not.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"ΔSUVpeak Prediction of Overall Survival, Progression Free Survival, and Lung Cancer Cause-specific Survival (ECOG-ACRIN)","type":"SECONDARY","unitOfMeasure":"percent change"}